Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by two referees whose comments to the authors are shown below. You will see that both referees are generally positive about your work and would support its ultimate publication in The EMBO Journal after appropriate revision. I would thus like to invite you to prepare a revised manuscript in which you need to address the referees' criticisms in an adequate manner.
I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Membrane receptors involved in plant innate immunity are very important players of plant pathogen response. The regulation of their activity is a major field of study that can also provide significant information on plant cell biology and cell biology in general. The present manuscript constitutes a significant, exciting advancement in this field. Starting from a search for loss of function mutants in MAMP signalling, the authors have identified one of the calreticulin genes and the single UDPglucose:glycoprotein transferase as important regulators of the synthesis of active EFR. The data reported are of excellent quality and most of the conclusions are convincing. The following points need to be addressed.
 The data in Figure 3 are interpreted to indicate that EFR synthesized in the psl1-4 and psl2-1 genetic backgrounds is not functional. It is however possible that EFR accumulated in these backgrounds upon inhibition of ERAD is retained in the ER; this is actually a very likely scenario given our knowledge on how ERQC works. ER retention would not allow proper signalling to occur even if the protein is functional. This hypothesis can be tested by analyzing the membrane distribution of EFR accumulated in the psl1-4 and psl2-1 genetic backgrounds upon kifunensine treatment. Any result of this experiment would be very interesting.
 The authors underline that before this study no physiological clients for the calreticulinclanexin-glucosyltransferase cycle had been identified in plants (page 4, end of second paragraph) and that this branch of quality control could be mainly limited to stress-response (page 190, last paragraph; page 12, end of third paragraph). This can be questioned. Calnexin associates with partially assembled oat vacuolar proton ATPase (Li et al1998, Plant Cell 10:119-130. Moreover, treatment with ER glucosidase inhibitors increases the rate of trimerization of the bean storage protein phaseolin, pointing to a role of the cycle of addition and removal of glucose residues in controlling the assembly of this protein (Lupattelli et al 1997, Plant Cell 9:597-609) . Phaseolin belongs to the 7S globulin class of storage proteins, an ancient class of proteins present also in ferns.
 In Figure 3D , EFR has markedly lower apparent molecular mass in the EM fraction than in the PM fraction. This deserves some comment. Could it be due to extensive elongation of the glycans during traffic through the Golgi complex?
 Figure 5E . The band representing undigested EFR has much higher mobility in lane 3 than in lane 1. Do the authors have any explanation?
 Page 8, third paragraph, Figures 5E and 5F are 3E and 3F.
Referee #2 (Remarks to the Author):
The ms by Saijo et al. describes a genetic screen to identify additional genes that affect immunity in Arabidopsis. The screen is elegant and employs anthocyanin accumulation as a convenient read-out of elf18 treatment. The genes identified are components of the N-glycosylation mechanism. The experiments are well-described and clearly support the main conclusions that glycosylation is important for the functioning of EFR but not for FLS2. The authors attribute this to accumulation of misfolded proteins in the ER.
There are a few points that I believe need attention.
1. The main evidence for the existence of misfolded EFR is a western blot ( figure 3E ) that show a reduced amount of EFR protein to be present in the psl mutants. There is no evidence that this is due to misfolding. In the absence of glycosylation there is usually reduced stability, but whether this can be fully attributed to aberrant folding is not really clear. I think the authors should modify their statement accordingly or provide evidence using additional methods such as protease sensitivity and/or CD measurements on in vitro or in vivo produced EFR proteins to support their conclusion concerning protein folding. The statement on p. 7: "Together, we conclude that PSL1 and PSL2 are required for stable accumulation of functional EFR" is the right one and this terminology should be used throughout. 2. The effects of the weak psl alleles are a very important observation due to the disconnection between levels of protein and residual biological activity that they show. The experiments would be even more insightful if they can be presented slightly more quantitative. Using FLS2 as a control it would be good to determine how much activity is left (3F) and how much protein remains (3E 
Our reply:
This is a valid point. There are at least two possible scenarios in which stabilized EFR becomes "biologically" non-functional as our data indicate: (1) improperly folded and/or N-glycosylated EFR is not signaling competent, and (2) biochemically functional EFR is not delivered to its functional cellular compartment(s). We have thus mentioned in the revised text the latter possibility that signaling-competent EFR is retained in the ER (page 8). We have also avoided stating that "misfolded" EFR is targeted for ERAD in the psl mutants, as the referee 2 concerns, but instead suggested in the revised text a contribution of active ERAD to the decrease of EFR steady-state levels. As for the suggested experiments, we wish to point out the fact that the functional intracellular site(s) of EFR is currently still unknown. Thus, we are concerned that at present the obtained results in such experiments would not strongly support either possibility. Rather, we have initiated extensive studies towards a deeper understanding of this question, using integrated cell biological, biochemical and genetic approaches. In this research program, we must carefully examine the localization of the receptor and its potential dynamics in the presence and absence of the ligand in the wild type as well as in psl mutant plants. As this is part of a long-term effort and a project on its own, we request to keep this issue out of the scope of this manuscript.
The authors underline that before this study no physiological clients for the calreticulin-calnexinglucosyltransferase cycle had been identified in plants (page 4, end of second paragraph) and that this branch of quality control could be mainly limited to stress-response (page 190, last paragraph; page 12, end of third paragraph). This can be questioned. Calnexin associates with partially assembled oat vacuolar proton ATPase (Li et al1998, Plant Cell 10:119-130. Moreover, treatment with ER glucosidase inhibitors increases the rate of trimerization of the bean storage protein phaseolin, pointing to a role of the cycle of addition and removal of glucose residues in controlling the assembly of this protein (Lupattelli et al 1997, Plant Cell 9:597-609). Phaseolin belongs to the 7S globulin class of storage proteins, an ancient class of proteins present also in ferns.

Our reply:
This is in principle a valid point. These previous studies provided biochemical evidence such that calnexin is co-immunoprecipitated with the vacuolar proton ATPase in the former and in vitro translation of phaseolin is perturbed in the presence of ER glucosidase inhibitors. Although these data suggest a role of the CRT/CNX/UGGT cycle on plant protein biogenesis, we would not think that they clearly define "physiological" client proteins of this ERQC system. However, to be more specific and fair, we have revised our text to state that "the plant CNX/CRT/UGGT cycle has not been genetically defined to date". Figure 3D , EFR has markedly lower apparent molecular mass in the EM fraction than in the PM fraction. This deserves some comment. Could it be due to extensive elongation of the glycans during traffic through the Golgi complex?
In
Our reply: This is very likely the result of different buffer contents since in previous studies with other nonglycosylated membrane proteins we observed similar apparent size differences. We have thus mentioned in Figure legend 3D : "Apparent size difference between the EM and PM fractions is typical with this analysis, reflecting their different buffer composition."
Figure 5E. The band representing undigested EFR has much higher mobility in lane 3 than in lane 1. Do the authors have any explanation?
Our reply: By chance the band representing undigested EFR was loaded in the very end of the protein gel. Thus, this is an edge effect of this gel.
Page 8, third paragraph, Figures 5E and 5F are 3E and 3F.
Our reply:
We have corrected this accordingly.
Referee #2 (Remarks to the Author): The ms by Saijo et al. describes a genetic screen to identify additional genes that affect immunity in Arabidopsis. The screen is elegant and employs anthocyanin accumulation as a convenient read-out of elf18 treatment. The genes identified are components of the N-glycosylation mechanism. The experiments are well-described and clearly support the main conclusions that glycosylation is important for the functioning of EFR but not for FLS2. The authors attribute this to accumulation of misfolded proteins in the ER.
There are a few points that I believe need attention. 
The main evidence for the existence of misfolded EFR is a western blot (figure 3E
)
Our reply:
"Germline" has been deleted in the revised text. "Malfolded" has been changed to misfolded. "Gogi" was changed to Golgi. Regarding the ~ 150 and 100 kDa versions of EFR detected by in vitro incubation of plant protein extracts with radio-labeled ligands, we have added in the revised text on pg. 8 that it is still "unclear whether both forms exist in vivo". Nevertheless, both bands are specific because they are absent in respective efr and fls2 mutant samples and are competed upon addition of unlabeled elf18 and flg22 peptides. "α1,2-mannosidases" (page 8) -has been changed to "α-1,2-mannosidases. Thank you for sending us your revised manuscript. Our original referee 2 has now seen it again. You will be pleased to see that he/she is now positive about publication of your paper.
Still, there is one remaining editorial issue that needs further attention.
Prior to acceptance of every paper we perform a final check for figures containing lanes of gels that are assembled from cropped lanes. While cropping and pasting may be considered acceptable practices in some cases (please see Rossner and Yamada, JCB 166, 11-15, 2004 ) there needs to be a proper indication in all cases where such processing has been performed according to our editorial policies. Please note that it is our standard procedure when images appear like they have been pasted together without proper indication (like a white space or a black line between) to ask for the original scans (for our records).
In the case of the present submission there are a number of panels that do not fully meet these requirements: Figure 1E , figure 2C , figure 3D .
I therefore like to kindly ask you to send us a new version of the manuscript that contains suitably amended versions of these figures. I feel that it would also be important to mention in the relevant figure legends that all lanes come from the same gel. Please be reminded that according to our editorial policies we also need to see the original scans for the figures in question.
I am sorry to have to be insistent on this at this late stage. However, we feel that it is in your as well as in the interest of our readers to present high quality figures in the final print version of the paper.
Thank you very much for your cooperation. Please let us have a suitably amended manuscript as soon as possible.
